Annual Report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual Patient Report for 2023 and Annual Treatment Report for 2018

IF 1.7 4区医学 Q3 OBSTETRICS & GYNECOLOGY

Journal of Obstetrics and Gynaecology Research Pub Date : 2026-09-07 DOI:10.1111/jog.70476

Hiroaki Kajiyama, Satoshi Tamauchi, Fumiaki Takahashi, Toyomi Satoh, Board members of the 2025 Committee on Gynecologic Oncology of the Japan Society of Obstetrics and Gynecology

{"title":"Annual Report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual Patient Report for 2023 and Annual Treatment Report for 2018","authors":"Hiroaki Kajiyama, Satoshi Tamauchi, Fumiaki Takahashi, Toyomi Satoh, Board members of the 2025 Committee on Gynecologic Oncology of the Japan Society of Obstetrics and Gynecology","doi":"10.1111/jog.70476","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aim</h3>\n \n <p>To provide information including the trend of gynecological malignancies in Japan, we hereby present the Annual Patient Report for 2023 and the Annual Treatment Report for 2018 on the outcomes of patients who started treatment in 2018.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>The Japan Society of Obstetrics and Gynecology maintains an annual tumor registry, where information on gynecological malignancies from various participating institutions is gathered. The data of patients whose treatment with gynecologic malignancies was initiated in 2023 were analyzed retrospectively. Survival of the patients who started treatment with cervical, endometrial, and ovarian cancer in 2018 was analyzed by using the Kaplan–Meier, log-rank, and Wilcoxon tests.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Treatment was initiated in 2023 for 8061 patients with cervical cancer, 15 455 with endometrial cancer, 8844 with ovarian, tubal, and peritoneal cancer, 2316 with ovarian borderline tumors, and with the others (230 vulvar cancer, 157 vaginal cancer, 533 uterine sarcoma, 54 uterine adenosarcoma, 132 trophoblastic diseases). This clinicopathological information was summarized as the Patient Annual Report. The 5-year survival rates of the patients who initiated treatment in 2018 were as follows. For cervical cancer, the rates were 92.6%, 75.7%, 57.3%, and 25.9% for Stages I, II, III, and IV, respectively. For endometrial cancer, the rates were 94.3%, 88.3%, 75.2%, and 32.1% for Stages I, II, III, and IV, respectively. For ovarian cancer, the rates were 90.9%, 79.2%, 53.4%, and 41.1% for Stages I, II, III, and IV, respectively.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>The annual tumor report is an important survey that provides knowledge on gynecological malignancy trends in Japan.</p>\n </section>\n </div>","PeriodicalId":16593,"journal":{"name":"Journal of Obstetrics and Gynaecology Research","volume":"52 9","pages":""},"PeriodicalIF":1.7000,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Obstetrics and Gynaecology Research","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jog.70476","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim

To provide information including the trend of gynecological malignancies in Japan, we hereby present the Annual Patient Report for 2023 and the Annual Treatment Report for 2018 on the outcomes of patients who started treatment in 2018.

Methods

The Japan Society of Obstetrics and Gynecology maintains an annual tumor registry, where information on gynecological malignancies from various participating institutions is gathered. The data of patients whose treatment with gynecologic malignancies was initiated in 2023 were analyzed retrospectively. Survival of the patients who started treatment with cervical, endometrial, and ovarian cancer in 2018 was analyzed by using the Kaplan–Meier, log-rank, and Wilcoxon tests.

Results

Treatment was initiated in 2023 for 8061 patients with cervical cancer, 15 455 with endometrial cancer, 8844 with ovarian, tubal, and peritoneal cancer, 2316 with ovarian borderline tumors, and with the others (230 vulvar cancer, 157 vaginal cancer, 533 uterine sarcoma, 54 uterine adenosarcoma, 132 trophoblastic diseases). This clinicopathological information was summarized as the Patient Annual Report. The 5-year survival rates of the patients who initiated treatment in 2018 were as follows. For cervical cancer, the rates were 92.6%, 75.7%, 57.3%, and 25.9% for Stages I, II, III, and IV, respectively. For endometrial cancer, the rates were 94.3%, 88.3%, 75.2%, and 32.1% for Stages I, II, III, and IV, respectively. For ovarian cancer, the rates were 90.9%, 79.2%, 53.4%, and 41.1% for Stages I, II, III, and IV, respectively.

Conclusion

The annual tumor report is an important survey that provides knowledge on gynecological malignancy trends in Japan.

查看原文本刊更多论文

日本妇产科学会妇科肿瘤委员会年度报告：2023年年度患者报告和2018年年度治疗报告。

目的：为了提供日本妇科恶性肿瘤趋势等信息，我们在此提供2023年患者年度报告和2018年开始治疗的患者的2018年治疗报告。方法：日本妇产科学会维护一个年度肿瘤登记处，收集来自各参与机构的妇科恶性肿瘤信息。回顾性分析我院2023年开始妇科恶性肿瘤治疗的患者资料。使用Kaplan-Meier、log-rank和Wilcoxon检验分析2018年开始治疗的宫颈癌、子宫内膜癌和卵巢癌患者的生存。结果：2023年开始治疗宫颈癌患者8061例，子宫内膜癌患者15455例，卵巢癌、输卵管癌和腹膜癌患者8844例，卵巢交界性肿瘤患者2316例，其他患者（外阴癌230例，阴道癌157例，子宫肉瘤533例，子宫腺肉瘤54例，滋养细胞疾病132例）。这些临床病理信息被总结为患者年度报告。2018年开始治疗的患者5年生存率如下：至于子宫颈癌，第一、二、三、四期的发病率分别为92.6%、75.7%、57.3%和25.9%。对于子宫内膜癌，I期、II期、III期和IV期的发病率分别为94.3%、88.3%、75.2%和32.1%。对于卵巢癌，I期、II期、III期和IV期的发病率分别为90.9%、79.2%、53.4%和41.1%。结论：年度肿瘤报告是了解日本妇科恶性肿瘤趋势的重要调查。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Obstetrics and Gynaecology Research 医学-妇产科学

CiteScore

3.10

自引率

0.00%

发文量

376

审稿时长

3-6 weeks

期刊介绍： The Journal of Obstetrics and Gynaecology Research is the official Journal of the Asia and Oceania Federation of Obstetrics and Gynecology and of the Japan Society of Obstetrics and Gynecology, and aims to provide a medium for the publication of articles in the fields of obstetrics and gynecology. The Journal publishes original research articles, case reports, review articles and letters to the editor. The Journal will give publication priority to original research articles over case reports. Accepted papers become the exclusive licence of the Journal. Manuscripts are peer reviewed by at least two referees and/or Associate Editors expert in the field of the submitted paper.